Chugai Pharmaceutical Co. Ltd (CHGCF PINK) stock market data APIs
$54.5477
-15.98(-29.3%)
as of April 17, 2025
Chugai Pharmaceutical Co. Ltd Financial Data Overview
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; and research collaboration and option to license agreement with Araris Biotech AG to develop ADCs using Araris AraLinQ technology. The company was founded in 1925 and is headquartered in Chuo-ku, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
Prev. Close
54.5477
Open
38.5635
High
60.4725
Low
38.5635
52 wk Range
29.1675-60.37
Market Cap
99 341 M
P/E Ratio
36.811
Shares Outstanding
1 646 M
Revenue
1 170 611 M
EPS
0.3651
Dividends (Yield)
0.0118
Beta
0.7
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Chugai Pharmaceutical Co. Ltd data using free add-ons & libraries
Get Chugai Pharmaceutical Co. Ltd Fundamental Data
Chugai Pharmaceutical Co. Ltd Fundamental data includes:
- Net Revenue: 1 170 611 M
- EBITDA: 573 668 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-12-31
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Chugai Pharmaceutical Co. Ltd News
New
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
A downtrend has been apparent in Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) lately. While the stock has lost 8.2% over the past week, it could witness a trend reversal as a hammer chart p...
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Upgraded to Buy: Here's Why
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend i...
U.S. Stocks Rise as Economic Growth Continues
The S&P 500, Nasdaq Composite and Dow industrials all ended higher after data showed the U.S. defied projections of a recession last year. Continue reading
U.S. Stocks Rise After GDP Data
The Nasdaq Composite turned lower as stocks pared gains from a stronger-than-expected fourth-quarter GDP report. Continue reading
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
